Previous 10 | Next 10 |
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
2023-11-01 06:31:38 ET More on Cerevel Therapeutics Cerevel: Drop On Data Delay For EMPOWER Program Provides Buy Opportunity Cerevel Therapeutics prices $450M stock Cerevel downgraded at Bank of America on delayed readouts Seeking Alpha’s Quant Rating ...
Raised $499 million of net proceeds from public offering of common stock, expected to support operations into 2026 2024 data readout timelines for emraclidine, darigabat, and tavapadon remain on track Tavapadon investor webcast scheduled for December 11, 2023 Conference ...
Cerevel Therapeutics Holdings Inc. (CERE) is expected to report $-0.63 for Q3 2023
2023-10-18 07:07:15 ET More on Cerevel Therapeutics Cerevel: Drop On Data Delay For EMPOWER Program Provides Buy Opportunity Cerevel Therapeutics prices $450M stock For further details see: Cerevel Therapeutics says Perceptive Advisors buys 876.8K shares
CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2023 financial results and business updates on Wedn...
2023-10-12 05:30:22 ET More on Cerevel Therapeutics Cerevel: Drop On Data Delay For EMPOWER Program Provides Buy Opportunity Cerevel downgraded at Bank of America on delayed readouts Cerevel Therapeutics falls on delayed data readouts Seeking Alpha’s Q...
CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten public offering of 19,728,189 s...
2023-10-11 16:05:17 ET More on Cerevel Therapeutics Cerevel downgraded at Bank of America on delayed readouts Seeking Alpha’s Quant Rating on Cerevel Therapeutics Cerevel Therapeutics falls on delayed data readouts For further details see: Cerevel ...
CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics , (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in the Morgan Stanley 21st Annual Global Healt...
News, Short Squeeze, Breakout and More Instantly...
2024-07-10 10:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 12:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / May 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVie") (NYSE:ABBV). Investors who purchased Cerevel and continue to holdto the present are enco...